Methylation status and immunohistochemistry of BRCA1 in epithelial ovarian cancer

14Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

Background: Cancer initiation and progression are controlled by genetic and epigenetic events. One epigenetic process which is widely known is DNA methylation, a cause of gene silencing. If a gene is silenced the protein which it encodes will not expressed. Objectives: 1. Identify the methylation status of BRCA1 in patients with epithelial ovarian cancer (EOC)and assess BRCA1 protein expression in tumor tissue. 2. Examine whether BRCA1 gene methylation and BRCA1 protein are associated with survival of epithelial ovarian cancer patients. Methods: The study design was a prospective-cohort study, conducted at Sardjito hospital, Yogyakarta, Indonesia. Results: A total of 69 cases were analyzed in this study. The data showed that the methylation status of BRCA1 in EOC was positive in 89.9%, with clear protein expression of BRCA1 in 31.9%. Methylation status and expression of BRCA1 were not prognosticators of EOC patients. Menarche, CA125 level, clinical stage and residual tumor were independent factors for prognosis.

Cite

CITATION STYLE

APA

Pradjatmo, H., Dasuki, D., Anwar, M., & Mubarika, S. (2014). Methylation status and immunohistochemistry of BRCA1 in epithelial ovarian cancer. Asian Pacific Journal of Cancer Prevention, 15(21), 9479–9485. https://doi.org/10.7314/APJCP.2014.15.21.9479

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free